Kevin SJ Thompson, Ph.D. Selected Publications (from 30):

• Baker JG, Fromont C, Bruder M, Thompson KSJ, Kellam B, Hill SJ, Gardiner SM, Fischer PM (2020). Using esterase selectivity to determine the in vivo duration of systemic availability and abolish systemic side-effects of topical β-blockers. ACS Pharmacology & Translational Science (accepted)

• Baker JG, Gardiner SM, Woolard J, Fromont C, Jadhav GP, Mistry SN, Thompson KSJ, Kellam B, Hill SJ, Fischer PM (2017). Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. FASEB J. 31(7): 3150–3166.

• Rich RL, Papalia GA, Flynn PJ, Furneisen J, Quinn J, Klein JS, Katsamba PS, Waddell MB, Scott M, Thompson J, Berlier J, Corry S, Baltzinger M, Zeder-Lutz G, Schoenemann A, Clabbers A, Wieckowski S, Murphy MM, Page P, Ryan TE, Duffner J, Ganguly T, Corbin J, Gautam S, Anderluh G, Bavdek A, Reichmann D, Yadav SP, Hommema E, Pol E, Drake A, Klakamp S, Chapman T, Kernaghan D, Miller K, Schuman J, Lindquist K, Herlihy K, Murphy MB, Bohnsack R, Andrien B, Brandani P, Terwey D, Millican R, Darling RJ, Wang L, Carter Q, Dotzlaf J, Lopez-Sagaseta J, Campbell I, Torreri P, Hoos S, England P, Liu Y, Abdiche Y, Malashock D, Pinkerton A, Wong M, Lafer E, Hinck C, Thompson K, at al. A global benchmark study using affinity-based biosensors. Anal Biochem. 386(2):194-216

• Godber B, Frogley M, Rehak M, Sleptsov A, Thompson KS, Uludag Y, Cooper MA (2007). Profiling of molecular interactions in real time using acoustic detection. Biosens Bioelectron 22(9-10):2382-6.

• Li X, Thompson KS, Godber B, Cooper MA (2006). Quantification of small molecule-receptor affinities and kinetics by acoustic profiling. Assay Drug Dev Technol. 4(5):565-73.

• Godber B, Thompson KSJ, Rehak M, Uludag Y, Kelling S, Sleptsov A, Frogley M, Wiehler K, Whalen C and Cooper MA (2005). Direct quantification of analyte concentration by Resonant Acoustic Profiling^TM (RAP^TM), Clinical Chemistry 51(10):1962-1972.

• Kent TC, Thompson KSJ and Naylor LH (2005). Development of a Generic Dual Reporter Gene Assay for Screening GPCRs. Journal of Biomolecular Screening 10(5):437-446.

• Islam A, Thompson KSJ, Akhtar S and Handley SL (2004). Increased 5-HT_2A receptor expression and function following central glucocorticoid receptor knockdown in vivo. Eur J Pharmacol 502(3):213-220.

• Sheerin A, Thompson KSJ and Goyns MH (2002). Altered composition of the AP-1 transcription factor in immortalized compared to normal proliferating cells. Cancer Lett. 177(1):83-7.

• Sheerin A, Thompson KSJ and Goyns MH (2001). Altered composition and DNA binding activity of the AP-1 transcription factor during the ageing of human fibroblasts. Mech Ageing Dev 122(15):1813-24.

• Smith SL, Thompson KSJ, Sargent BJ and Heal DJ (2001). BTS 72 664: a novel CNS drug with potential anticonvulsant, neuroprotective and antimigraine properties. CNS Drug Reviews 7:146-171.

• Islam A, Handley SL, Thompson KSJ, and Akhtar S (2000). Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems. J Drug Targetting 7:373-382.

• Phillips I, Martin KF, Thompson KSJ and Heal, DJ (1998). GABA-evoked depolarisations in the rat cortical wedge: involvement of GABA_A receptors and HCO₃^– Brain Res 798:330-332.

• Phillips I, Martin KF, Thompson KSJ and Heal DJ (1997). Weak blockade of AMPA-receptor mediated depolarisations in the rat cortical wedge by phenytoin but not lamotrigine or carbamazepine. European J Pharmacol 337:189-195.